- The Myeloma Beacon - https://myelomabeacon.org -

CX-4945

By: Admin; Published: April 20, 2009 @ 9:18 pm | Comments Disabled

Brand Name:
Generic Name:
Code Name: CX-4945
Company: Cylene
FDA Clinical Phase: 1

Description:

CX-4945 is an oral anti-cancer agent.  It inhibits CK2, an enzyme that plays a role in the development of cancerous cells through cellular processes such as cell cycle regulation, cellular signaling, blood vessel formation, inflammation, and cellular proliferation.

Clinical Trials:
For a list of clinical trials studying CX-4945 for the treatment of multiple myeloma, see ClinicalTrials.gov [1].

Source: Cylene Pharmaceuticals, http://www.cylenepharma.com/cylene/cx_4945 [2] (as of November 14, 2009)

Article printed from The Myeloma Beacon: https://myelomabeacon.org

URL to article: https://myelomabeacon.org/resources/2009/04/20/cx-4945/

URLs in this post:

[1] ClinicalTrials.gov: http://www.clinicaltrial.gov/ct2/results?term=&recr=&rslt=&type=&cond=multiple+myeloma&intr=CX-4945&outc=&lead=&spons=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&rcv_s=&rcv_e=&lup_s=&lup_e=

[2] http://www.cylenepharma.com/cylene/cx_4945: http://www.cylenepharma.com/cylene/cx_4945

Copyright © The Beacon Foundation for Health. All rights reserved.